Please select the option that best describes you:
What is your preferred regimen for metastatic clear cell renal cell carcinoma with CNS disease?
(assuming that the patient is int-poor risk, has measurable disease outside of the CNS, warrants treatment with appropriate PS)
Answer from: Medical Oncologist at Academic Institution
There is little to no data to guide tx of CNS mets in mRCC. I always treat such patients with local tx to CNS prior to systemic therapy (e.g., SBRT). The data in melanoma of benefit to untreated CNS mets have not extended to RCC, so I am not currently comfortable starting therapy without prior local...
Sign in or Register to read more